31
Mar
Mar
Boehringer Ingelheim and the Decrease Franconian biotech firm EMFRET Analytics own signed a cooperation and license settlement for the preclinical improvement program of the GPVI-blocking antibody EMA601. The Würzburg College Hospital supported the improvement of this novel lively ingredient from the start. EMA601 particularly targets the platelet floor receptor glycoprotein VI (GPVI). Research carried out […]